COMPARISON OF BEDTIME INSULIN GLARGINE VERSUS TWICE-DAILY NPH AMONG INNER CITY ETHNIC MINORITY TYPE 2 DIABETIC PATIENTS UNCONTROLLED ON BEDTIME NPH AND ORAL AGENTS

被引：0
|
作者：
Hsia, S. H. [1 ]
机构：
[1] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2010年 / 58卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
520
引用
收藏
页码：252 / 252
页数：1
相关论文
共 50 条
  • [41] Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
    Lau, E.
    Salem, A.
    Chan, J. C. N.
    So, W. Y.
    Kong, A.
    Lamotte, M.
    Luk, A.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
  • [42] Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes
    da Silva, Giordana Maluf
    Nogueira, Katia Camarano
    Fukui, Rosa Tsuneshiro
    Soares Correia, Marcia Regina
    dos Santos, Rosa Ferreira
    Rossi da Silva, Maria Elizabeth
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (44) : 6716 - 6721
  • [43] A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes
    Benedetti, MM
    Humburg, E
    Dressler, A
    Ziemen, M
    HORMONE AND METABOLIC RESEARCH, 2003, 35 (03) : 189 - 196
  • [44] Comparison of metformin and sulphonylurea (gliclazide) in combination with daily NPH insulin in type 2 diabetic patients inadequately controlled on maximal oral therapy.
    McNulty, S
    Mangnall, M
    Benbow, S
    Hardy, K
    DIABETES, 1997, 46 : 622 - 622
  • [45] Economics of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes
    Sclar, DA
    Evans, MA
    White, JR
    Skaer, TL
    Robison, LM
    DIABETOLOGIA, 2005, 48 : A335 - A335
  • [46] Economics of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes
    Sclar, DA
    Evans, MA
    White, JR
    Skaer, TL
    Robison, LM
    DIABETES, 2005, 54 : A607 - A607
  • [47] Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects A randomized cross-over study
    Lucidi, Paola
    Porcellati, Francesca
    Rossetti, Paolo
    Candeloro, Paola
    Cioli, Patrizia
    Marzotti, Stefania
    Andreoli, Anna Marinelli
    Fede, Raffaela
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES CARE, 2011, 34 (06) : 1312 - 1314
  • [48] Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial
    Rosenstock, Julio
    Fonseca, Vivian
    Schinzel, Stefan
    Dain, Marie-Paule
    Mullins, Peter
    Riddle, Matthew
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (05) : 742 - 749
  • [49] Comparison of treatment satisfaction of twice-daily BIAsp 70/30 with once-daily insulin glargine in patients with type 2 diabetes
    Brod, M
    Lammert, M
    Raskin, P
    DIABETES, 2005, 54 : A114 - A114
  • [50] Lower incidence of nocturnal hypoglycaemia in patients with Type 2 diabetes treated with insulin glargine compared with NPH insulin, given as a combination regimen with oral agents.
    Benedetti, MM
    Hamburg, E
    Dressler, A
    Ziemen, M
    DIABETOLOGIA, 2002, 45 : A259 - A259
12345